4basebio
4basebio is a biotechnology manufacturing company producing GMP-grade synthetic DNA for use in cell and gene therapies, mRNA vaccines and genome editing applications.
Using an enzymatic, cell-free synthesis process, the company manufactures application-specific linear DNA constructs that overcome the purity and scalability limitations of conventional plasmid-based systems.
4basebio holds MHRA GMP certification for clinical-grade manufacture and also develops non-viral nanoparticle delivery systems for genetic medicine applications.
Latest News
4basebio Raises £15M in Placing and Subscription
4basebio has conditionally raised about £15.0 million through a placing and subscription, with M&G Investment Management, Elevage Medical Technologies and 2Invest AG among the investors, alongside a retail offer of up to £0.5 million. The raise is subject to shareholder approval at a general meeting expected around 6 November 2026.
4basebio Partners with TriLink to Supply Tier 1 Pharma Cell Therapy Programme
4basebio has partnered with TriLink BioTechnologies to supply a Tier 1 pharmaceutical company's Phase I cell therapy programme, providing clinical-grade opDNA synthetic DNA as the starting material. TriLink will manufacture the mRNA drug substance using its CleanCap co-transcriptional capping technology.
4basebio Expands Synthetic DNA Offering for Personalised mRNA Medicines
4basebio has expanded its synthetic DNA offering to supply starting material for personalised mRNA medicines. The expansion runs across its high quality and cGMP operations in Cambridge, adding shortened manufacturing turnaround times, patient-specific batch sizes and rapid batch release for individualised treatment programmes.